Cortagen is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Pro, or AEDP) from the Khavinson group's family of "peptide bioregulators" — short sequences reverse-engineered from tissue extracts and studied for tissue-specific effects. Its reputation centers on nerve repair, but that reputation rests on a narrow and preclinical evidence base: a handful of rat and in-vitro experiments, largely from a single Russian laboratory, with almost no independent Western replication.
The most important distinction up front is that Cortagen is the synthetic analog of Cortexin, a brain-cortex tissue extract used clinically in Russia. The clinical track record belongs to the extract, not to the synthetic peptide. What follows reports what the published Cortagen research actually documented — animal nerve-regeneration data, in-vitro tissue-culture effects, and a gene-expression hypothesis — and where each finding sits on the evidence ladder.
Research-context information only. Cortagen is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
How Cortagen Works
The mechanism attributed to Cortagen is a hypothesis, not a settled pathway. The Khavinson group proposes that ultrashort peptides act as gene-expression regulators — binding regulatory DNA regions and shifting the transcription of specific genes in the tissue the peptide was derived from. Under this framework, Cortagen (designed from cerebral-cortex extract) is expected to act preferentially on nervous tissue.
The direct support for this idea is molecular and in-vitro. A microarray study reported that five days of Cortagen injections altered the expression of roughly 110 identifiable genes in mouse heart tissue (PMID 15159690) — evidence that the peptide reaches tissue and shifts transcription, though the study was in heart, not brain. Separately, an organotypic tissue-culture study reported that Cortagen produced a tissue-specific stimulation of explant growth, promoting growth in cultures from the same tissue class its parent extract came from (PMID 11713572). Both are mechanism-level, preclinical findings — they describe molecular activity, not a clinical benefit. The dosing figures circulating in community sources are not derived from human pharmacology; see the Cortagen dosing guide for the honest provenance of those numbers.
Peripheral Nerve Regeneration (Rat Models)
The single most-cited claim for Cortagen is nerve regeneration, and it is the strongest-evidenced — though "strongest" here still means small, single-lab animal work. A Khavinson-group rat study reported that Cortagen accelerated the regeneration of a surgically transected sciatic nerve, with faster restoration of nerve structure in treated animals than in controls (PMID 11276314). A companion study reported a delayed effect: Cortagen-treated rats showed improved recovery of injured-nerve function that became apparent over a longer follow-up window (PMID 12134478).
Both findings come from rat models of peripheral-nerve injury, from the group that developed the peptide, and neither has been independently reproduced by an unaffiliated Western laboratory. They should be read as an early, preclinical signal that this sequence did something measurable to nerve regeneration in rats — not as evidence of nerve repair in humans. No controlled human trial of synthetic Cortagen has tested this outcome.
Ready to buy? Compare verified vendors on our best Cortagen sources page, or browse all coupon codes for up to 50% off.
